

ATTACHMENT A

Research Roundtable of the Alzheimer's Association Topic Meetings Record of Publications

MCI Meeting, September 2004:

Alzheimer Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned? Grundman, M., Petersen, R.C., Bennett, D., Feldman, H., Salloway, S., Jelle Visser, P., Thal, L.J., Schenk, D., Khachaturian, Z., & Thies, W. *Alzheimer's & Dementia* (2006).

Biomarkers Meeting, April 2005:

Role of biomarkers in studies of presymptomatic Alzheimer's disease. Morris, J.C., Quaid K., K.A., Holtzman, D.M., Kantarci, K., Kaye, J., Reiman, E.M., Klunk, W.E., & Siemers, E.R. *Alzheimer's & Dementia* (2005).

The role of biomarkers in clinical trials for Alzheimer's disease. Thal, L.J., Kantarci, K., Reiman, E.M., Klunk, W.E., Weiner, M.W., Zetterberg, H., Galasko, D., Pratico, D., Griffin, S., Schenk, D., Siemers, E. *Alzheimer's Disease & Associated Disorders* (2006).

Optimal Trial Design Meeting, November 2005:

Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Mohs, R.C., Kawas, C., Carrillo, M.C. *Alzheimer's & Dementia* (2006).

Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease". Siemers, E.R. *Alzheimer's & Dementia* (2006).

Disease modification in multiple sclerosis: Issues with relevance to clinical trial designs in Alzheimer's disease. Rudick, R.A. *Alzheimer's & Dementia* (2006).

Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Knopman, D. *Alzheimer's & Dementia* (2006).

Disease-modifying treatments for Alzheimer's disease: A perspective based on experience with R-Flubiprofen. Wilcock, G.K. *Alzheimer's & Dementia* (2006).

Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed. Aisen, P.S., *Alzheimer's & Dementia* (2006).

Lessons from osteoporosis clinical trials. Silverman, S.L. *Alzheimer's & Dementia* (2006).

Policy statement on voting by persons with dementia residing in long-term care facilities. Karlawish, J., Appelbaum, P.S., Bonnie, R., Karlan, P., & McConnell, S. *Alzheimer's & Dementia* (2006).

ATTACHMENT A

Research Roundtable of the Alzheimer's Association Topic Meetings Record of Publications

Perspectives on assessing benefits and risks in clinical trials for Alzheimer's disease. McConnell, S., Karlawish, J., Vellas, B., & DeKosky, S. *Alzheimer's & Dementia* (2006).

Cytoskeletal Meeting, April 2006:

Perspective: Cytoskeletal Modulators and Pleiotropic Strategies for Alzheimer Drug Discovery. Schenk, D., Carrillo, M.C., & Trojanowski, J.Q. *Alzheimer's & Dementia* (2006).

Lipitor's effect in Alzheimer's dementia (LEADe) Study. Hey-Hadavi, J., *Alzheimer's & Dementia* (2006).

The last stand: The dichotomy of chaperone function in Alzheimer's disease. Dickey, C.A. & Petrucelli, L. *Alzheimer's & Dementia* (2006).

Dietary energy intake and the pathogenesis of Alzheimer's disease. Mattson, M.P. *Alzheimer's & Dementia* (2006).

Pleiotropic Approaches to Alzheimer's and Other Diseases of Aging. Cole, G., & Frautschy, S.A. *Alzheimer's & Dementia* (2006).

Health Economics & Real World Value of AD Therapy, November 2006:

Perspective: Health Economics and Value of Therapy in Alzheimer's Disease. Schwam, E.M., Abu-Shakra, S., del Valle, M., Townsend, R.J., Carrillo, M.C. & Fillit, H. *Alzheimer's & Dementia* (2007).

Wimo, A. & Norlund, A. Cost-effectiveness studies. *Alzheimer's & Dementia* (2007).

Frank, L. Report from the Alzheimer's Association Research Roundtable: Patient reported outcomes and dementia research. *Alzheimer's & Dementia* (2007).

Ready, R. Patient reported outcomes in clinical trials for Alzheimer's disease. *Alzheimer's & Dementia* (2007).

Vellas, B., Froelich, L., Sampaio, C. Value therapy for Alzheimer's Disease: A European point of view. *Alzheimer's & Dementia* (2007).

Cohen, J.T. & Neumann, P.J. Modeling Alzheimer's Disease: State of the art and future directions. *Alzheimer's & Dementia* (2007).

ATTACHMENT A

Research Roundtable of the Alzheimer's Association Topic Meetings Record of Publications

Banerjee, S. Quality of life in dementia – DEMQOL – development of a disease-specific measure of HRQOL in dementia and an illustration of its use in research and clinical practice. *Alzheimer's & Dementia* (2007).

Jones, R. Drug treatment of AD: the UK experience – NICE guidance and guidelines for dementia. *Alzheimer's & Dementia* (2007).

Lancot, K. Cholinesterase inhibitors in Alzheimer's disease: evidence-based or evidence-biased? *Alzheimer's & Dementia* (2007).

Academic/Industry Interface for Alzheimer's Drug Discovery, April 2007

Iverson, A.J., Lane, R., May, P.C., Hosford, D.A., Carrillo, M.C. & Siemers, E.R. Perspective: The academic/industry interface for Alzheimer's drug discovery. *Alzheimer's & Dementia* (2008).

Early Risk Assessment for Alzheimer's Disease, November 2007

Carrillo, MC, Blackwell, A, Hampel, H, Lindborg, J, Sperling, R, Schenk, D, Sevigny, JJ, Ferris, S, Bennett, DA, Craft, S, Hsu, T, Klunk, W. Perspective: Early Risk Assessment for Alzheimer's Disease. 2009. *Alzheimer's & Dementia*; pp.182-196.

Scales for Alzheimer's Diseases, April 2008

Black, R, Greenberg, B, Ryan, JM, Posner, H, Seeburger, J, Amatniak, J, Resnick, M, Mohs, R, Miller, DS, Saumnier, D, Carrillo, MC, Stern, Y. Scales as Outcome Measures for Alzheimer's Disease. 2009. *Alzheimer's & Dementia*; 5:pp324-339.

Optimal Trial Design for Alzheimer's Drug Discovery, November 2008

In preparation

Alzheimer's Disease Classification, April 2009

In Preparation

Global Clinical Trials in Alzheimer's Drug Development, November 2009